Long Shot: Revance’s RT002 May Banish Frown Lines for 7 Months
Revance's investigational injectable—RT002—achieves median duration of 7 months, a phase 2 active comparator study now underway.
Revance's investigational injectable—RT002—achieves median duration of 7 months, a phase 2 active comparator study now underway.
Integrating retail skincare into plastic surgery practices improves patient outcomes, boosts satisfaction, and supports healing. By offering medical-grade products tailored to each procedure, surgeons can provide comprehensive care while enhancing practice revenue and reputation. Learn how skincare aligns with surgical results to set new standards in patient care and practice growth.